Decreasing the probability of creatine phosphokinase elevations: clinical considerations for daptomycin dosing in obese patients.
Donovan
Brian J
BJ
Mohr
John F
JF
Knapp
Andrew G
AG
Eisenstein
Barry I
BI
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D016470:Bacteremia / Q000188:drug therapy*; D003402:Creatine Kinase / Q000097:blood*; D017576:Daptomycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D009765:Obesity / Q000150:complications*; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D003402:Creatine Kinase; D017576:Daptomycin